LLY · ELI LILLY & Co · Financials
$1,417.54
+43.84 (+3.19%)
At close · Oct 30
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$1.29T
Shares
940.75M
Volume · Oct 30
5.29M
Avg daily vol (3M)
2.56M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$65.18B
+44.7%
FY2025
Net Income
$20.64B
+94.9%
FY2025
Gross Margin
83.04%
+1.7pp
FY2025
Diluted EPS
$22.95
+96%
FY2025
Operating Cash Flow
$16.81B
+90.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $85B – $87B | $86.46B | $65.18BG | $45.04BG | $34.12BG | $28.54BG | $28.32BG | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B | $19.96B | $19.62B | $23.11B | $22.6B | $24.29B | $23.08B | $21.84B | $20.37B | $18.63B | |
| — | $14.15B | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B | $5.71B | $5.04B | $4.93B | $4.91B | $4.8B | $5.07B | $4.37B | $4.25B | $4.38B | $4.25B | |
| — | $72.31B | $54.13B | $36.63B | $27.04B | $21.91B | $21.01B | $19.06B | $17.6B | $16.81B | $15.53B | $15.51B | $14.92B | $14.68B | $18.21B | $17.81B | $19.22B | $18.71B | $17.59B | $16B | $14.38B | |
| — | — | 83.04% | 81.31% | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 77.73% | 73.09% | 74.76% | 74.85% | 78.76% | 78.78% | 79.13% | 81.08% | 80.55% | 78.52% | 77.2% | |
| — | $15.38B | $13.34B | $10.99B | $9.31B | $7.19B | $6.93B | $5.98B | $5.6B | $5.05B | $5.1B | $5.31B | $4.8B | $4.73B | $5.53B | $5.28B | $5.02B | $4.88B | $4.33B | $3.84B | $3.49B | |
| — | $12.62B | $11.09B | $8.59B | $7.4B | $6.44B | $6.43B | $6.12B | $6.21B | $5.98B | $5.98B | $6.53B | $6.53B | $6.62B | $7.13B | $7.51B | $7.88B | $7.05B | $6.89B | $6.63B | $6.1B | |
| — | — | $488M | $553M | $506M | $579.7M | $628.8M | $428.2M | $225.8M | $361.3M | $462.2M | $687.9M | $631.8M | $535.9M | $555M | $563M | $469M | $385.7M | — | — | — | |
| — | $2.17B | $2B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.5B | $1.43B | $1.38B | $1.45B | $1.46B | $1.37B | $1.33B | $1.3B | $1.12B | -$1.05B | |
| — | — | $895M | $781M | $485.9M | $331.6M | $339.8M | $359.6M | $400.6M | $242.5M | $225M | $185.2M | $161.2M | $148.8M | $160.1M | $177.8M | $186M | $185.5M | $261.3M | -$228.3M | — | |
| — | — | — | $175.2M | $173.6M | $62.8M | $25.4M | $33M | $80.4M | $159.3M | $166.4M | $108.7M | $87M | $121M | $119.7M | $105M | $79.9M | $51.9M | $75.2M | -$210.7M | — | |
| — | -$108M | -$571M | -$219M | $97M | -$320.9M | -$201.6M | $1.17B | $291.6M | $145.6M | $301.5M | $112.8M | $100.6M | $340.5M | $518.9M | $674M | -$179M | -$5M | -$229.5M | $26.1M | $122M | |
| — | — | — | -$49.8M | -$23.5M | -$420M | $178M | $1.44B | $403.1M | $27M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $34.77B | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B | $2.3B | $3.37B | $2.79B | $3B | $5.89B | $4.9B | $6.14B | $6.77B | $5.36B | -$1.31B | $3.88B | |
| — | $7.19B | $5.09B | $2.09B | $1.31B | $561.6M | $573.8M | $1.04B | $628M | $529.5M | $2.39B | $636.4M | $381.6M | $609.8M | $1.2B | $1.32B | $1B | $1.46B | $1.03B | $764.3M | $923.8M | |
| — | $27.58B | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | -$204.1M | $2.74B | $2.41B | $2.39B | $4.68B | $4.09B | $4.35B | $5.07B | $4.33B | -$2.07B | $2.95B | |
| — | — | 31.67% | 23.51% | 15.36% | 21.88% | 19.71% | 25.24% | 37.27% | 15.04% | -1.02% | 12.9% | 12.07% | 12.19% | 20.27% | 18.09% | 17.9% | 21.97% | 19.82% | -10.17% | 15.85% | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $4.09B | $4.35B | $5.07B | $4.33B | -$2.07B | — | |
| — | $28.16B | $22.08B | $10.6B | $4.76B | $6.74B | $7.74B | $6.22B | $7.54B | $3.32B | -$29.6M | $2.09B | $1.82B | $401.4M | $6.48B | $4.15B | $3.16B | $4.87B | $4.64B | -$4.87B | $4.35B | |
| USD/shares | — | $30.86 | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 | $8.93 | $3.14 | -$0.19 | $2.59 | $2.27 | $2.23 | $4.33 | $3.67 | $3.90 | $4.58 | $3.94 | -$1.89 | — |
| USD/shares | $35.50 – $36.50* | $30.81 | $22.95G | $11.71G | $5.80G | $6.90G | $6.12 | $6.79G | $8.89 | $3.13 | -$0.19 | $2.58 | $2.26 | $2.23 | $4.32 | $3.66 | $3.90 | $4.58 | $3.94 | -$1.89 | — |
| shares | — | — | 897.3M | 900.6M | 900.2M | 901.74M | 906.96M | 907.63M | 931.06M | 1.03B | 1.05B | 1.06B | 1.06B | 1.07B | 1.08B | 1.11B | 1.11B | 1.11B | 1.1B | 1.09B | — |
| shares | — | — | 899.3M | 904.1M | 903.3M | 904.62M | 911.68M | 912.51M | 935.68M | 1.03B | 1.05B | 1.06B | 1.07B | 1.07B | 1.08B | 1.12B | 1.11B | 1.11B | 1.1B | 1.09B | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $24.03B in buybacks, $51.46B in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Latest reported total
USD 43,400,000,000
As of Mar 31, 2026
Tracked instruments
0
Loans, facilities and note series
Annual baseline
Dec 31, 2025
Latest approved annual total
Reported total debt history
| As of | Reported label | Amount | Source |
|---|---|---|---|
| 2026-03-31 | total debt | USD 43,400,000,000 |
10-Q filed 2026-04-30
As of March 31, 2026, total debt was $43.4 billion, an increase of $0.9 billion compared with $42.5 billion as of December 31, 2025. |
| 2025-12-31 | total debt | USD 42,500,000,000 |
10-K filed 2026-02-12
As of December 31, 2025, total debt was $42.5 billion, an increase of $8.9 billion compared with $33.6 billion at December 31, 2024. See Note 11 to the consolidated financial statements for additional information. |
| 2024-12-31 | total debt | USD 33,600,000,000 |
10-K filed 2026-02-12
As of December 31, 2025, total debt was $42.5 billion, an increase of $8.9 billion compared with $33.6 billion at December 31, 2024. See Note 11 to the consolidated financial statements for additional information. |
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current debt and lease obligations | 2026-09-30 | USD 2,517,000,000 | 10-Q filed 2026-10-29 |
| Noncurrent debt carrying amount | 2026-09-30 | USD 46,986,000,000 | 10-Q filed 2026-10-29 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
15.46×
Peer median 7.11×
EV/EBIT
—
P/E (TTM)
44.59×
Peer median 41.82×
Peer medians compare against the 6 similar-size Drug Manufacturers - General companies (of 15 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $65,179,000,000 | $45,043,000,000 | $34,124,000,000 | $28,541,400,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $43,481,000,000 | $30,375,000,000 | $21,791,000,000 | $18,190,000,000 | $16,811,000,000 | $14,229,300,000 | $12,722,600,000 | $12,391,900,000 |
| Non Us | $21,698,000,000 | $14,668,000,000 | $12,333,000,000 | $10,351,300,000 | $11,507,400,000 | $10,310,500,000 | $9,596,800,000 | $9,101,400,000 |
| Europe | $11,558,000,000 | $6,921,000,000 | $6,175,000,000 | $4,299,200,000 | $4,776,800,000 | $4,187,700,000 | $3,765,000,000 | $3,663,100,000 |
| Rest of World | $6,057,000,000 | $4,271,000,000 | $2,946,000,000 | $2,852,000,000 | — | — | — | — |
| Japan | $2,132,000,000 | $1,815,000,000 | $1,673,000,000 | $1,747,300,000 | $2,367,000,000 | $2,583,100,000 | $2,547,600,000 | $2,407,400,000 |
| China | $1,951,000,000 | $1,660,000,000 | $1,540,000,000 | $1,452,800,000 | $1,661,400,000 | $1,116,900,000 | $939,400,000 | $750,800,000 |
| Other Foreign Countries | — | — | $2,946,200,000 | $2,852,000,000 | $2,702,200,000 | $2,422,700,000 | $2,344,900,000 | $2,280,100,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $60,958,000,000 | $40,748,000,000 | $28,814,000,000 | $25,462,800,000 | $25,957,900,000 | $22,694,800,000 | $20,377,300,000 | $19,866,400,000 |
| Collaboration and Other Revenue | $4,221,000,000 | $4,295,000,000 | $5,310,000,000 | $3,078,600,000 | $2,360,500,000 | $1,845,000,000 | $1,942,200,000 | $1,626,900,000 |
| Jardiance | $3,432,000,000 | $3,341,000,000 | $2,745,000,000 | $2,066,000,000 | $1,490,800,000 | $1,153,800,000 | $944,200,000 | $658,300,000 |
| Bamlanivimab | — | — | — | — | — | $871,200,000 | — | — |
| Basaglar | — | $676,900,000 | $728,300,000 | $760,400,000 | $892,500,000 | $1,124,400,000 | $1,112,600,000 | $801,200,000 |
| COVID19 Antibodies | — | $0 | $0 | $2,020,000,000 | $2,240,000,000 | $871,200,000 | — | — |
| Olumiant | — | $957,400,000 | $922,600,000 | $830,500,000 | $1,115,100,000 | $638,900,000 | $426,900,000 | $202,500,000 |
| Trajenta BI | — | — | $386,900,000 | $383,700,000 | $372,500,000 | $358,500,000 | $590,600,000 | $574,700,000 |
| TYVYT | — | $526,000,000 | $393,400,000 | $293,300,000 | $418,100,000 | $308,700,000 | $134,000,000 | — |
| Royalty | — | — | $191,600,000 | $163,400,000 | $175,000,000 | $135,600,000 | $301,500,000 | $303,200,000 |
Key facts
CIK
59478
CUSIP
532457108
13F (30d)
2065 filings
2008 filers
Visit website
Investor relations